Related Experiment Video
Updated: Jan 30, 2026

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
Success of immune checkpoint blockade therapies - mechanisms and implications for hepatology
Bertram Bengsch1,2, Robert Thimme1
1Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, University Medical Center Freiburg, Faculty of Medicine, Germany.
Abstract:
The success of immune modulation by checkpoint blockade approaches is currently transforming oncology, with high and long-lasting tumor responses in patients with advanced disease across many cancer entities. Rooted in the reinvigoration of adaptive antitumor immune responses through disinhibition of negative feedback pathways, these approaches are particularly effective in patients with significant preexisting T cell responses in tumors with high neoantigen load. While promising data is starting to emerge from clinical trials in liver cancer patients, the underlying immunobiology remains poorly understood. In this review, we discuss the immunological mechanisms underlying the success of current checkpoint blockade therapies and the implications for hepatology including management of immune-related hepatitis. Checkpoint blockade therapy provides novel therapeutic options for difficult-to-treat liver cancers but also novel clinical challenges for hepatologists facing immune-related adverse events.
Insights
Immune checkpoint blockade therapy is revolutionizing cancer treatment, showing promise in liver cancer by boosting anti-tumor immune responses. However, understanding its complex immunobiology and managing immune-related side effects remains crucial for hepatologists.
Area of Science:
- Oncology
- Immunology
- Hepatology
Background:
- Immune checkpoint blockade therapies are transforming oncology, yielding durable responses in advanced cancers.
- These therapies reinvigorate adaptive antitumor immunity by releasing negative feedback pathways.
- Effectiveness is highest in patients with pre-existing T cell responses and high neoantigen tumors.
Purpose of the Study:
- To review the immunological mechanisms of checkpoint blockade therapies.
- To discuss the implications of these therapies for liver cancer treatment.
- To highlight challenges in managing immune-related adverse events in hepatology.
Main Methods:
- Literature review of current checkpoint blockade therapies.
- Analysis of immunological mechanisms and clinical trial data in liver cancer.
- Discussion of clinical challenges and management strategies for hepatologists.
Main Results:
- Checkpoint blockade shows promise in liver cancer clinical trials.
- Understanding the underlying immunobiology is essential for optimizing treatment.
- Immune-related adverse events, such as hepatitis, present new clinical challenges.
Conclusions:
- Checkpoint blockade offers novel therapeutic options for challenging liver cancers.
- Further research into immunobiology is needed to improve efficacy and safety.
- Hepatologists require specific knowledge to manage immune-related side effects effectively.
More Related Videos
Related Concept Videos
Ecological Succession
Neuromuscular Junction And Blockade
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
What is the Immune System?
Humoral Immune Responses
Gene Therapy

